What is HC Wainwright's Estimate for RARE Q2 Earnings?

Key Points

• HC Wainwright has issued a Q2 2025 earnings estimate of **($1.27) per share** for Ultragenyx Pharmaceutical, maintaining a **"Buy" rating** with a target price of **$80.00**.
• Recent price targets from other analysts show a downward trend, with Wells Fargo lowering its target price from **$88.00 to $65.00** and Morgan Stanley from **$65.00 to $55.00**.
• Insider selling was noted, as Director Corazon D. Sanders sold **2,405 shares** at an average price of **$37.39**, reducing their stake by **13.55%**.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for Ultragenyx Pharmaceutical in a note issued to investors on Monday, July 28th. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will earn ($1.27) per share for the quarter. HC Wainwright has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($5.14) EPS, Q1 2026 earnings at ($1.83) EPS, Q2 2026 earnings at ($1.59) EPS, Q3 2026 earnings at ($1.41) EPS, Q4 2026 earnings at ($1.05) EPS and FY2026 earnings at ($5.88) EPS.

RARE has been the topic of a number of other research reports. Wedbush reduced their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research report on Monday, July 14th. Morgan Stanley reduced their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Guggenheim restated a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. William Blair assumed coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Finally, Wells Fargo & Company cut their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $82.57.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded up $1.12 during trading hours on Wednesday, reaching $28.44. 2,239,592 shares of the company were exchanged, compared to its average volume of 3,190,304. The company has a market capitalization of $2.69 billion, a P/E ratio of -4.84 and a beta of 0.25. Ultragenyx Pharmaceutical has a 1-year low of $25.81 and a 1-year high of $60.37. The business has a 50 day moving average of $33.99 and a 200 day moving average of $37.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The firm had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. During the same period in the previous year, the company posted ($2.03) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.0% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RARE. GAMMA Investing LLC raised its position in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 323 shares during the last quarter. Parallel Advisors LLC grew its holdings in Ultragenyx Pharmaceutical by 1,061.9% during the 2nd quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 669 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth about $35,000. ANTIPODES PARTNERS Ltd acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $57,000. Finally, Headlands Technologies LLC acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $59,000. 97.67% of the stock is currently owned by institutional investors.

Insider Activity at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares in the company, valued at approximately $573,712.16. This represents a 13.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.